Early work demonstrated that imatinib-resistant CML cell lines remain highly sensitive to resveratrol, which suppresses cell proliferation and induces apoptosis, highlighting its potential to overcome resistance linked to BCR-ABL mutations [147]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.